MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:02 2024-06-14 pm EDT | ||
| 14.86 EUR | +2.06% |
|
| Current month | +12.93% | ||
| 1 month | +15.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 14.86 | +2.06% |
| 24-06-13 | 14.56 | -0.27% |
| 24-06-12 | 14.6 | -0.07% |
| 24-06-11 | 14.6 | -1.55% |
| 24-06-10 | 14.84 | +1.02% |
Real-time Euronext Paris
Last update June 14, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| UF5KB | |
| ISIN | FRBNPP05KAB7 |
| Date issued | 2023-03-31 |
| Strike | 443.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.46 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.93 € |
|---|---|
| Lowest since issue | 2.305 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
979.7
DKK
Average target price
934.3
DKK
Spread / Average Target
-4.64%
- Stock Market
- Certificates
- UF5KB Certificat
